Matches in SemOpenAlex for { <https://semopenalex.org/work/W2413612383> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2413612383 endingPage "16" @default.
- W2413612383 startingPage "505" @default.
- W2413612383 abstract "Lymphomas are among the tumors most responsive to chemotherapeutic agents and radiation therapy. Despite chemotherapeutic and radiological advances, tumor cell resistance still remains a problem, and the toxicity of chemotherapy and radiation therapy limits their potential. Less toxic therapies for lymphoma have been continued to search for effectiveness. Since the discovery of the hybridoma technology by Kohler and Milstein in 1975, utilizing antibodies as targeted therapy for lymphoma has been investigated for many years. After 20 years of clinical trials, monoclonal antibody therapy of lymphoma enters the new millennium ready for 'prime time'. Investigators' early enthusiasm was dampened by problems with tumor targeting, HAMA, and allergic reactions, but important advances in molecular biology and chelation chemistry have led to new and improved reagents. Rituximab(IDEC-C2B8) has already been approved by the FDA in USA and the Ministry of Welfare and Labour in Japan for relapsed CD20-positive lymphomas and indolent B-cell lymphoma including mantle cell lymphoma, respectively. Ibritumomab tiuxetan and iodine-131 anti-B1 antibody have an excellent anti-lymphoma profile, and both appear to have higher response rates than rituximab. Results from the rituximab vs. ibritumomab tiuxetan phase III trial clearly favor the latter especially in %CR. Radiolabeled Lym-1, T101, LL2, and anti-Tac data will be forthcoming. Continued refinements of immunotoxins will establish their possible therapeutic role, and a variety of antibody conjugates including drugs, prodrugs, nonprotein toxins, and other agents, will continue to be studied in the clinic. Bispecific antibodies for lymphoma are also in early clinical testing. Over the next 10 years, many of the major advances in lymphoma therapy will be antibody-based." @default.
- W2413612383 created "2016-06-24" @default.
- W2413612383 creator A5015509689 @default.
- W2413612383 date "2002-03-01" @default.
- W2413612383 modified "2023-10-14" @default.
- W2413612383 title "[Development of monoclonal antibody therapy for malignant lymphoma]." @default.
- W2413612383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11904966" @default.
- W2413612383 hasPublicationYear "2002" @default.
- W2413612383 type Work @default.
- W2413612383 sameAs 2413612383 @default.
- W2413612383 citedByCount "0" @default.
- W2413612383 crossrefType "journal-article" @default.
- W2413612383 hasAuthorship W2413612383A5015509689 @default.
- W2413612383 hasConcept C115085202 @default.
- W2413612383 hasConcept C126322002 @default.
- W2413612383 hasConcept C143998085 @default.
- W2413612383 hasConcept C159654299 @default.
- W2413612383 hasConcept C203014093 @default.
- W2413612383 hasConcept C2776146153 @default.
- W2413612383 hasConcept C2777058707 @default.
- W2413612383 hasConcept C2777257650 @default.
- W2413612383 hasConcept C2777525834 @default.
- W2413612383 hasConcept C2778515704 @default.
- W2413612383 hasConcept C2779338263 @default.
- W2413612383 hasConcept C2780653079 @default.
- W2413612383 hasConcept C502942594 @default.
- W2413612383 hasConcept C542903549 @default.
- W2413612383 hasConcept C71924100 @default.
- W2413612383 hasConceptScore W2413612383C115085202 @default.
- W2413612383 hasConceptScore W2413612383C126322002 @default.
- W2413612383 hasConceptScore W2413612383C143998085 @default.
- W2413612383 hasConceptScore W2413612383C159654299 @default.
- W2413612383 hasConceptScore W2413612383C203014093 @default.
- W2413612383 hasConceptScore W2413612383C2776146153 @default.
- W2413612383 hasConceptScore W2413612383C2777058707 @default.
- W2413612383 hasConceptScore W2413612383C2777257650 @default.
- W2413612383 hasConceptScore W2413612383C2777525834 @default.
- W2413612383 hasConceptScore W2413612383C2778515704 @default.
- W2413612383 hasConceptScore W2413612383C2779338263 @default.
- W2413612383 hasConceptScore W2413612383C2780653079 @default.
- W2413612383 hasConceptScore W2413612383C502942594 @default.
- W2413612383 hasConceptScore W2413612383C542903549 @default.
- W2413612383 hasConceptScore W2413612383C71924100 @default.
- W2413612383 hasIssue "3" @default.
- W2413612383 hasLocation W24136123831 @default.
- W2413612383 hasOpenAccess W2413612383 @default.
- W2413612383 hasPrimaryLocation W24136123831 @default.
- W2413612383 hasRelatedWork W1497156528 @default.
- W2413612383 hasRelatedWork W1987641426 @default.
- W2413612383 hasRelatedWork W2012409020 @default.
- W2413612383 hasRelatedWork W2014239970 @default.
- W2413612383 hasRelatedWork W2084493022 @default.
- W2413612383 hasRelatedWork W2140497341 @default.
- W2413612383 hasRelatedWork W2148853365 @default.
- W2413612383 hasRelatedWork W2167459757 @default.
- W2413612383 hasRelatedWork W2413612383 @default.
- W2413612383 hasRelatedWork W2600006134 @default.
- W2413612383 hasVolume "60" @default.
- W2413612383 isParatext "false" @default.
- W2413612383 isRetracted "false" @default.
- W2413612383 magId "2413612383" @default.
- W2413612383 workType "article" @default.